EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1

Jianliang Xu iD, Tongqing Zhou iD, Krisha McKee, Baoshan Zhang, Cuiping Liu, Alexandra F Nazzari, Amarendra Pegu, Chen-Hsiang Shen, Jordan E Becker, Michael F Bender, Payton Chan, Anita Changela und 22 weitere

Advanced Science · 2024-07 · 11 (26)

DOI: 10.1002/advs.202309268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 05.05.2024. Verfasst von Jianliang Xu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. Hauptthemen laut MEDLINE: HIV-1, Antibodies, Bispecific, Camelids, New World, Antibodies, Neutralizing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Office of AIDS Research, NIAID, NIH, Intramural NIH HHS, Frederick National Laboratory for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Broadly neutralizing antibodies are proposed as therapeutic and prophylactic agents against HIV‐1, but their potency and breadth are less than optimal. This study describes the immunization of a llama with the prefusion‐stabilized HIV‐1 envelope (Env) trimer, BG505 DS‐SOSIP, and the identification and improvement of potent neutralizing nanobodies recognizing the CD4‐binding site (CD4bs) of vulnerability. Two of the vaccine‐elicited CD4bs‐targeting nanobodies, G36 and R27, when engineered into a triple tandem format with llama IgG2a‐hinge region and human IgG1‐constant region (G36×3‐IgG2a and R27×3‐IgG2a), neutralized 96% of a multiclade 208‐strain panel at geometric mean IC 80 s of 0.314 and 0.033 µg mL −1 , respectively. Cryo‐EM structures of these nanobodies in complex with Env trimer revealed the two nanobodies to neutralize HIV‐1 by mimicking the recognition of the CD4 receptor. To enhance their neutralizing potency and breadth, nanobodies are linked to the light chain of the V2‐apex‐targeting broadly neutralizing antibody, CAP256V2LS. The resultant human‐llama bispecific antibody CAP256L‐R27×3LS exhibited ultrapotent neutralization and breadth exceeding other published HIV‐1 broadly neutralizing antibodies, with pharmacokinetics determined in FcRn‐Fc mice similar to the parent CAP256V2LS. Vaccine‐elicited llama nanobodies, when combined with V2‐apex broadly neutralizing antibodies, may therefore be able to fulfill anti‐HIV‐1 therapeutic and prophylactic clinical goals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Antibodies, BispecificCamelids, New WorldAntibodies, NeutralizingAnimalsHumansHIV AntibodiesHIV InfectionsMice

Stichwörter der Autor:innen

HIV‐1bNAbbispecific antibodiesbroadly neutralizing antibodyllamaneutralizing nanobodiesvaccinationvaccine

Substanzen

Antibodies, BispecificAntibodies, NeutralizingHIV Antibodies

Autor:innen und Institutionen

  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Laboratory of Lymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 20892, USA.
  • Department of Biology, Georgia State University, Atlanta, GA, 30303, USA.
  • Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, 10027, USA.
  • Department of Biochemistry and Molecular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
  • Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.

ORCID-Profile: Jianliang Xu, Tongqing Zhou, Peter D Kwong

Förderung

  • Office of AIDS Research, NIAID, NIH
  • Intramural NIH HHS
  • Frederick National Laboratory for Cancer Research
  • NCI NIH HHS
  • CCR NIH HHS
  • National Cancer Institute
  • Vaccine Research Center

Zitieren

APA

Xu, J., Zhou, T., McKee, K., Zhang, B., Liu, C., Nazzari, A. F., Pegu, A., Shen, C. H., Becker, J. E., Bender, M. F., Chan, P., Changela, A., Chaudhary, R., Chen, X., Einav, T., Kwon, Y. D., Lin, B. C., Louder, M. K., Merriam, J. S., …, & Kwong, P. D. (2024). Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1. Advanced Science, 11(26). https://doi.org/10.1002/advs.202309268

Vancouver

Xu J, Zhou T, McKee K, Zhang B, Liu C, Nazzari AF, et al. Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1. Advanced Science. 2024;11(26). doi:10.1002/advs.202309268

BibTeX
@article{Xu2024,
  author = {Xu, Jianliang and Zhou, Tongqing and McKee, Krisha and Zhang, Baoshan and Liu, Cuiping and Nazzari, Alexandra F and Pegu, Amarendra and Shen, Chen-Hsiang and Becker, Jordan E and Bender, Michael F and Chan, Payton and Changela, Anita and Chaudhary, Ridhi and Chen, Xuejun and Einav, Tal and Kwon, Young Do and Lin, Bob C and Louder, Mark K and Merriam, Jonah S and Morano, Nicholas C and O'Dell, Sijy and Olia, Adam S and Rawi, Reda and Roark, Ryan S and Stephens, Tyler and Teng, I-Ting and Tourtellott-Fogt, Emily and Wang, Shuishu and Yang, Eun Sung and Shapiro, Lawrence and Tsybovsky, Yaroslav and Doria-Rose, Nicole A and Casellas, Rafael and Kwong, Peter D},
  title = {Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {26},
  doi = {10.1002/advs.202309268}
}
Kostenlos starten →